|
|
| (38 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT[[Anaplastic large cell lymphoma]] |
| {{SI}}
| |
| {{DiseaseDisorder infobox |
| |
| Name = auses
| |
| | |
| Anaplastic large cell lymphoma, ALK negative
| |
| | |
| ls|
| |
| ICD10 = {{ICD10|C|84|4|c|81}} |
| |
| OMIM = |
| |
| MedlinePlus = |
| |
| eMedicineSubj = |
| |
| eMedicineTopic = |
| |
| }}
| |
| {{CMG}}; {{AE}} {{AP}}
| |
| | |
| {{SK}} ALCL-ALK(-); ALK-negative ALCL; ALK negative ALCL; ALK negative anaplastic large cell lymphoma
| |
| | |
| ==Overview==
| |
| The ALK negative anaplastic large cell lymphoma is a [[peripheral T-cell lymphoma]] [[Non-Hodgkin's lymphoma]]. ALK negative ALCL [[T-cell]]s express [[CD30]], but not the ALK ('''A'''naplastic '''L'''ymphoma '''K'''inase) chimeric protein,<ref name=Swerdlow>{{cite book | last = Swerdlow | first = Steven | title = WHO classification of tumours of haematopoietic and lymphoid tissues | publisher = International Agency for Research on Cancer | location = Lyon, France | year = 2008 | isbn = 9789283224310 }}</ref> reason why the clinical outcome is more variable than the [[ALK(+)-ALCL]].<ref name="pmid25461779">{{cite journal| author=Xing X, Feldman AL| title=Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. | journal=Adv Anat Pathol | year= 2015 | volume= 22 | issue= 1 | pages= 29-49 | pmid=25461779 | doi=10.1097/PAP.0000000000000047 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25461779 }} </ref> Instead, this [[T-cell]]s have a chromosomal rearrangement, affecting DUSP22 and TP63 gene. ALK(-) patients with DUSP22 mutation have shown to have a higher five-year overall survival rate in comparison to [[ALK(+)-ALCL]].<ref name="pmid24894770">{{cite journal| author=Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA et al.| title=ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. | journal=Blood | year= 2014 | volume= 124 | issue= 9 | pages= 1473-80 | pmid=24894770 | doi=10.1182/blood-2014-04-571091 | pmc=PMC4148769 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24894770 }} </ref>
| |
| | |
| ==Historical Perspective==
| |
| The WHO added the ALK(-) ALCL as a provisional entity since 2008 in the [[peripheral T-cell lymphoma]] classification.<ref>{{cite web|url=http://www.sciencedirect.com/science/article/pii/S104084281200131X|title=Anaplastic large cell lymphoma, ALK-negative}}</ref>
| |
| | |
| ==Classification==
| |
| ===Morphologic Classification===
| |
| | |
| ==Pathophysiology ==
| |
| | |
| ==Causes==
| |
| | |
| | |
| == Differential Diagnosis==
| |
| *Peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS)<ref name="pmid22789917">{{cite journal| author=Ferreri AJ, Govi S, Pileri SA, Savage KJ| title=Anaplastic large cell lymphoma, ALK-negative. | journal=Crit Rev Oncol Hematol | year= 2013 | volume= 85 | issue= 2 | pages= 206-15 | pmid=22789917 | doi=10.1016/j.critrevonc.2012.06.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22789917 }} </ref>
| |
| *Classical [[Hodgkin's lymphoma]]<ref name="pmid22789917">{{cite journal| author=Ferreri AJ, Govi S, Pileri SA, Savage KJ| title=Anaplastic large cell lymphoma, ALK-negative. | journal=Crit Rev Oncol Hematol | year= 2013 | volume= 85 | issue= 2 | pages= 206-15 | pmid=22789917 | doi=10.1016/j.critrevonc.2012.06.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22789917 }} </ref>
| |
| *Primary cutaneous anaplastic large cell lymphoma<ref name=Swerdlow>{{cite book | last = Swerdlow | first = Steven | title = WHO classification of tumours of haematopoietic and lymphoid tissues | publisher = International Agency for Research on Cancer | location = Lyon, France | year = 2008 | isbn = 9789283224310 }}</ref>
| |
| | |
| == Epidemiology and Demographics==
| |
| The ALK(-) ALCL represents 2%-3% of all [[NHL]] and 12% of all [[T-cell]] [[Non-Hodgkin's lymphomas]].<ref>{{cite web|url=http://www.sciencedirect.com/science/article/pii/S104084281200131X|title=Anaplastic large cell lymphoma, ALK-negative}}</ref>
| |
| | |
| ==Risk Factors==
| |
| *Breast implants<ref name="pmid22789917">{{cite journal| author=Ferreri AJ, Govi S, Pileri SA, Savage KJ| title=Anaplastic large cell lymphoma, ALK-negative. | journal=Crit Rev Oncol Hematol | year= 2013 | volume= 85 | issue= 2 | pages= 206-15 | pmid=22789917 | doi=10.1016/j.critrevonc.2012.06.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22789917 }} </ref>
| |
| | |
| ==Natural History, Complications and Prognosis==
| |
| | |
| ===Prognosis===
| |
| | |
| == Diagnosis ==
| |
| | |
| ===History and Symptoms===
| |
| | |
| ===Laboratory Findings===
| |
| | |
| == Treatment ==
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |